2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1260

Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study
Abstract Number: 1261

Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement
Abstract Number: 1262

The Importance of Standardization of Musculoskeletal Procedures Performed in an Academic Rheumatology Clinic
Abstract Number: 1263

Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)
Abstract Number: 1264

Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US
Abstract Number: 1265

The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Abstract Number: 1266

ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
Abstract Number: 1267

The Association between Clinically Suspect Arthralgia and Adipokines in Obese Patients
Abstract Number: 1268

Assessment of the Persistence of Crystals Under Polarised Light Microscopy in Stored Synovial Fluid Samples
Abstract Number: 1269

Influence of Diuretic-Response Sodium Transporter Genes on Renal Uric Acid Handling in Response to Frusemide
Abstract Number: 1270

Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Abstract Number: 1271

Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia
Abstract Number: 1272

Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Abstract Number: 1273

What Did Patients from the US Think about Their Gout in 2017?
Abstract Number: 1274

Atmospheric Temperature and the Incidence of Gout Flare: Data from the Korea Meteorological Association and National Health Insurance Service

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].